Pharma noshes at the biotech buffet

If 2007 was the year pharma woke up to biotech, then 2008 will be time for brunch. Drug makers will continue to serve themselves from the biologics buffet, whether by gobbling up entire companies or by snacking on a bit of this candidate and a bit of that one through licensing deals. Plus, back in the R&D kitchen, Big Pharma is working on its own biotech recipes, though none of them are likely to be ready for sampling yet.

There's one potential wrinkle in the tablecloth, though: Reportedly, "momentum is building" for a new FDA pathway for generic biologic drugs (biosimilars). In June, a Senate committee approved legislation that would open that door; now, the House is preparing to consider a similar bill. And biosimilars already are taking hold in Europe. Last week, regulators approved a copycat form of Epogen, the blockbuster anemia drug made by biotech big wheel Amgen.

- here's more about Pharma's anemia-centric love for biotech
- see this article on biosimilar legislation in the U.S.

Related Articles:
Big Pharma makes its big leap into biotech. Report
Lines blur as Big Pharma crosses borders into biotech. Report
Who's next on the biotech buyout hit list? Report
Biotech stocks surge as investors anticipate buyouts. Report